Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options

BMC Cancer. 2015 May 13;15:402. doi: 10.1186/s12885-015-1395-6.

Abstract

Background: Epithelioid hemangioendothelioma is a rare vascular tumor of borderline or low-grade malignancy. The lungs and liver are the two common primary organs affected. Metastatic disease was reported in more than 100 cases in the literature. However, no firm conclusions can be determined for recommended treatment options.

Case presentation: The current case presents a patient with metastatic pulmonary epithelioid hemangioendothelioma to the cervical and mediastinal lymph nodes, lungs and liver that has been treated with pazopanib for more than two years with PET avid complete metabolic response in the mediastinum and lungs, and long-lasting stable disease. Target therapies that block VEGFR have a logical base in this rare malignancy.

Conclusions: The current case is the first to report objective, long-lasting response to pazopanib.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Hemangioendothelioma, Epithelioid / diagnosis
  • Hemangioendothelioma, Epithelioid / drug therapy*
  • Hemangioendothelioma, Epithelioid / pathology
  • Humans
  • Immunohistochemistry
  • Indazoles
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology*
  • Middle Aged
  • Neoplasm Metastasis
  • Positron-Emission Tomography
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Sulfonamides / therapeutic use*
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Indazoles
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Sulfonamides
  • pazopanib
  • Receptors, Vascular Endothelial Growth Factor